image credit- shutterstock
Biocytogen Pharmaceuticals (Beijing), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP).
Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and sublicenses.
Dr Yuelei Shen, President and CEO of Biocytogen said, "This collaboration highlights the versatility of our fully human antibody platforms and the broad applications of antibodies beyond traditional therapeutics. By combining our antibody discovery expertise with Merck KGaA, Darmstadt, Germany’s established capabilities in LNPs, we look forward to accelerating the development of next-generation nucleic acid delivery solutions."
